Novotalk

Company Overview

Snapshot

Founded in March 2014, Novotalk operates with 1–10 employees, developing digital therapy solutions. The company has secured funding across three rounds from investors including Mount Sinai Ventures and Millhouse Capital, with a strategic investment from.

Business overview

Novotalk specializes in developing on-demand, self-directed speech and language teletherapy solutions for individuals with speech impairments. Its core product is a patented web and mobile application designed to provide self-directed speech therapy and training, particularly for people who stutter, enabling them to achieve fluent speech. The company serves the healthcare market, including patients, healthcare providers, clinics, and schools, operating within the Digital Health and Medical Technologies sector, specifically focusing on Digital Therapeutics.

Strategic signal

In July 2018, Novotalk entered a joint venture agreement with Mount Sinai Health System for commercialization in North America and future research and development collaborations. This partnership signifies a major strategic validation for Novotalk's technology and provides a clear pathway for market expansion and clinical integration within a prominent healthcare system, indicating strong growth potential and institutional trust in its digital therapy solutions.

Company Intelligence Q&A

What is Novotalk's primary offering?

Novotalk provides on-demand, self-directed speech and language teletherapy solutions through a patented web and mobile application, enabling individuals with speech impairments to practice and maintain fluent speech independently.

When was Novotalk founded?

Novotalk was founded in March 2014.

What significant partnership did Novotalk establish in 2018?

In July 2018, Novotalk signed a joint venture agreement with Mount Sinai Health System for commercialization in North America and future research and development collaborations.